The Nuclear Renaissance: Where Will America Get the Uranium? | Corey Dias - CEO, Anfield Energy

Send us Fan MailDavid Gottfried ( https://en.wikipedia.org/wiki/David_Gottfried ) helped create the modern green-building movement. LEED became a global phenomenon, green buildings went mainstream, and sustainability became part of corporate vocabulary. But David eventually came to a startling conclusion: maybe making individual buildings greener wasn't enough. Maybe the problem was the operating system underneath civilization itself. So what exactly is wrong with that operating system - and can we actually rewrite it ( https://regen360.net/ )?Today we're going to tackle a question that is both enormous and surprisingly practical: What if humanity's biggest problem isn't a lack of technology, money, or even scientific knowledge - but the operating system we've built underneath civilization itself?My guest today is someone uniquely qualified to ask that question.David Gottfried ( https://davidagottfried.substack.com/ ) is the founder of the U.S. Green Building Council ( https://www.usgbc.org/people/david-gottfried/0000012600 ) and the World Green Building Council ( https://worldgbc.org/article/the-making-of-a-movement/ ) - organizations that helped launch what became a global green-building movement.David founded the U.S. Green Building Council in the early 1990s and wrote the white paper that ultimately became the foundation for the LEED green-building rating system. Today, LEED spans 186 countries, with more than 29 billion square feet of certified green building space and hundreds of thousands of accredited professionals.  He subsequently helped create the World Green Building Council, which now connects green-building organizations across more than 85 countries.David has spent four decades working at the intersection of engineering, real estate, sustainability, entrepreneurship and systems change. He's also taught at Stanford for three decades, advised major corporations and governments, and worked directly on technologies ranging from carbon capture and mineralization to regenerative building systems.But after helping build the modern sustainability movement, David began asking a much harder question:What if sustainability itself isn't enough?What if the problem isn't simply the technologies we use, but the incentives, measurements and assumptions that determine how those technologies are deployed?That's the question at the heart of his new book, Regen360: An Operating System for a Regenerative Earth ( https://www.barnesandnoble.com/w/regen360-david-gottfried/1150108833?ean=9798895741368 ).David proposes something he calls RegenOS - an attempt to rethink the rules by which organizations, markets, technologies and individuals make decisions - and a framework called HOPE: Health on Planet Earth.And because this is Progress, Potential and Possibilities, we're also going to talk about something particularly fascinating: artificial intelligence.David argues that AI isn't inherently good or bad - it's an amplifier of whatever objectives and incentives we give it. So if we're going to build increasingly powerful AI systems, perhaps the question isn't simply what can AI do?Perhaps it's: What should we be asking AI to optimize for?These are all pretty ambitious ideas.But if David is right, maybe changing the world begins by changing the rules by which we define success.#DavidGottfried #Regen360 #RegenerativeEarth #RegenerativeDesign #Sustainability #GreenBuilding #LEED #USGBC #ClimateChange #ClimateAction #Regeneration #HOPE #HealthOnPlanetEarth #RegenOS #ArtificialIntelligence #AI #SustainableTechnology #SystemsThinking #FutureOfEarth #FutureOfCivilization #EnvironmentalInnovation #GreenTechnology #PlanetaryHealth #CircularEconomy #Innovation #ProgressPotentialAndPossibilitiesSupport the show

Send us Fan MailFor decades we've heard that our DNA determines our health, but scientists are increasingly realizing that's only part of the story.Every day, from before we're born until the day we die, we're exposed to thousands of chemicals, pollutants, particles, microbes, foods, medications, consumer products, building materials, and environmental factors that continuously interact with our biology.Scientists now refer to this lifetime collection of exposures as the human exposome, and many believe it may ultimately become as important as the Human Genome Project in understanding why we develop cancer, Alzheimer's disease, autoimmune disorders, infertility, asthma, obesity, cardiovascular disease, and countless other chronic illnesses.But measuring something as vast as every exposure throughout a lifetime sounds almost impossible.Today we're joined by three scientists from UL Research Institutes ( https://ul.org/ ) helping make that possible.Dr. Heather Whitehead, Ph.D. ( https://chemicalinsights.ul.org/our-people/heather-whitehead-phd/ ) is an analytical chemist developing cutting-edge methods to detect both known and previously unknown environmental contaminants, including PFAS and emerging chemicals.Dr. Kristin Isaacs, Ph.D. ( https://chemicalinsights.ul.org/our-people/kristin-isaacs-phd/ ) is one of the world's leading computational exposure scientists, building mathematical models that predict how people encounter complex mixtures of chemicals across their daily lives.Dr. John Wambaugh, Ph.D. ( https://chemicalinsights.ul.org/our-people/john-wambaugh-phd/ ) is a physicist and computational toxicologist whose work helps determine what actually happens once those chemicals enter the human body, transforming massive datasets into meaningful predictions about health.Together, we'll explore one of the biggest frontiers in environmental health - how understanding the exposome could fundamentally change medicine, public health, and even how each of us lives our daily lives.UL Research Institutes is a leading independent safety science organization with global reach, pursuing and applying science-driven knowledge to meet their mission of working for a safer world.#HumanExposome #Exposome #EnvironmentalHealth #ExposureScience #PFAS #Toxicology #Chemistry #PublicHealth #PrecisionMedicine #PreventiveMedicine #HumanHealth #EnvironmentalScience #ComputationalToxicology #Pharmacokinetics #AI #Science #Biotechnology #FutureOfMedicine #Healthcare #DiseasePreventionSupport the show

Send us Fan MailThere aren't enough mental-health professionals to assess everyone who needs help - and the people who need help most may sometimes be the least willing to ask for it. Now an Israeli AI platform called LIV is trying to change both sides of that equation: using an empathetic AI conversation to identify PTSD and other mental-health risks, triage patients, and give clinicians a structured picture before they ever enter the room.Iris Shtein is Co-Founder and CEO of Mentaily ( https://mentaily.com/ ), an Israeli health-tech company developing AI-powered tools for mental-health assessment and clinical decision support.Iris comes to this problem from a remarkably multidisciplinary background. She is a registered nurse who served in the Israel Defense Forces, including as Deputy Head of Medicine for the Southern Command, before moving into healthcare innovation and digital health at Sheba Medical Center. At Sheba's ARC Innovation Center, she led telemedicine and remote-care initiatives and later strategic partnerships.It was there that Iris became involved in the development of LIV, an AI-powered platform designed to conduct conversational psychiatric intake and triage, generate structured clinical summaries, help assess diagnosis and severity, and identify situations that may require more urgent clinical attention. LIV was developed with Sheba and technology partners including Microsoft, and Sheba says the platform has subsequently received approval from Israel's Ministry of Health as an AI-based psychiatric triage system.Today, Mentaily is taking LIV beyond the Israeli healthcare system, including work involving military and security populations and a collaboration with Walter Reed National Military Medical Center and the Henry M. Jackson Foundation focused on PTSD assessment.#AI #ArtificialIntelligence #MentalHealth #PTSD #PostTraumaticStressDisorder #MilitaryMentalHealth #Veterans #VeteranHealth #MentalHealthAwareness #Psychiatry #DigitalHealth #HealthTech #MedTech #HealthcareAI #GenerativeAI #AIHealthcare #MentalHealthTech #Trauma #PTSDTreatment #MilitaryMedicine #VeteransHealth #PsychologicalHealth #HealthcareInnovation #FutureOfHealthcare #IsraeliInnovation #WalterReed #ShebaMedicalCenter #Mentaily #LIVSupport the show

Send us Fan MailThe United States wants more nuclear power. AI companies want enormous amounts of electricity. And policymakers want greater energy independence. But there's a surprisingly basic question underneath all three ambitions: where are we going to get the uranium?Corey Dias is Co-Founder, Chief Executive Officer and Director of Anfield Energy ( https://anfieldenergy.com/ ), a company focused on developing uranium and vanadium resources in the United States.At the center of Anfield's strategy is the Shootaring Canyon Mill in Utah, which the company describes as one of only three licensed, permitted and constructed conventional uranium mills in the United States. Anfield is pursuing a hub-and-spoke model in which uranium and vanadium from multiple nearby mining projects can be processed through this centralized facility.Corey brings an interesting perspective to the business. Before co-founding and leading Anfield, he spent roughly two decades in capital markets, including institutional equity research at CIBC, equity research and institutional sales roles in Toronto, and a stint as a Vice President at Fortress Investment Group, where he was involved with a $400 million investment portfolio. He also worked in management consulting in Stockholm.Today, we're going to talk about the nuclear fuel supply chain, why uranium milling is such an important piece of that puzzle, how a hub-and-spoke model could accelerate domestic production, and what it will take to responsibly bring legacy uranium infrastructure back into operation.#NuclearEnergy #NuclearPower #Uranium #NuclearRenaissance #AI #ArtificialIntelligence #DataCenters #Energy #EnergySecurity #CleanEnergy #NuclearFuel #UraniumMining #NuclearIndustry #EnergyTransition #GridEnergy #Vanadium #EnergyStorage #AdvancedReactors #SMR #SmallModularReactors #ClimateTechnology #CleanTechnology #EnergyInnovation #AnfieldEnergy #CoreyDias #ProgressPotentialAndPossibilitiesSupport the show

Send us Fan MailThe world produces and consumes roughly 374 million metric tons of meat every year. But what if we could produce the same thing people love about meat - without raising the animal? Today we're asking whether biotechnology could fundamentally reinvent one of humanity's oldest industries.Bruce Friedrich ( https://en.wikipedia.org/wiki/Bruce_Friedrich ) is Founder and President of the Good Food Institute ( https://gfi.org/ ), a global nonprofit network of science think tanks working to accelerate innovation in plant-based and cultivated meat. GFI now has more than 240 full-time team members around the world, with scientists making up the plurality of its team.Bruce's journey to food innovation is anything but conventional. He grew up in Oklahoma surrounded by cattle ranches and oil wells, spent six years running a homeless shelter and soup kitchen in Washington, D.C., taught in inner-city Baltimore through Teach For America - where he was named his school's Teacher of the Year - and later earned a law degree from Georgetown, graduating magna cum laude.Bruce went on to spend more than a decade working in animal welfare and public policy before founding the Good Food Institute in 2016. His basic insight was that trying to persuade billions of people simply to stop eating meat was unlikely to work. What if, instead, science could produce the meat people love - same taste, texture and functionality - without requiring animals?That idea is the subject of Bruce's fascinating new book, Meat: How the Next Agricultural Revolution Will Transform Humanity’s Favorite Food - and Our Future ( https://meatbook.org/ ). The book argues that alternative proteins could become much more than an environmental or animal-welfare story. Bruce makes the case that they could have implications for global hunger, climate change, deforestation, antimicrobial resistance, pandemic prevention, food security, national security, economic competitiveness, and even the future of agriculture itself.And importantly, Bruce isn't arguing that everyone needs to become vegetarian or vegan. As he puts it, the book is about meat “at the macro level” - how meat is made and how it can be made better.Bruce is also a TED Fellow and Y Combinator alum, and his TED talk has been viewed more than 2.5 million times and translated into 30 languages. His writing has appeared in publications including The Wall Street Journal, Foreign Policy, Nature, and Wired, and he has appeared on programs and podcasts including PBS NewsHour, TED Radio Hour, The Ezra Klein Show, and Making Sense.#Meat #FutureOfFood #AlternativeProtein #CultivatedMeat #PlantBasedMeat #FoodTechnology #FoodScience #Biotechnology #SyntheticBiology #Agriculture #FoodSecurity #ClimateChange #Sustainability #Protein #AnimalAgriculture #CultivatedMeat #FoodInnovation #GoodFoodInstitute #BruceFriedrich #Science #Technology #Innovation #FutureOfFood #ClimateTech #GlobalFoodSystemSupport the show

Send us Fan MailEvery year, hundreds of thousands of people around the world receive life-saving organ transplants - new hearts, kidneys, lungs, and livers that offer patients a second chance at life.But transplantation is only the beginning of the journey.Because preventing organ rejection requires suppressing the immune system, transplant recipients become vulnerable to infections that most healthy people never even notice.One of the most important - and least understood - is cytomegalovirus, or CMV.More than half of adults worldwide carry this virus, often for life, without ever knowing it. Yet in patients who have undergone organ transplantation, CMV can reactivate and become one of the leading infectious complications, threatening not only a patient's health, but also the long-term success of the transplanted organ itself.Fortunately, advances in virology, immunology, and antiviral drug development are opening new possibilities for managing this complex disease.My guest today is Dr. Neil Inhaber, MD - Head, Marketed Products and Neuroscience, Global Medical Affairs at Takeda ( https://www.takeda.com/ ).Dr. Inhaber is a physician specializing in pulmonary and critical care medicine whose career uniquely bridges frontline patient care with the development of innovative therapies. Over the past three decades, he has held senior medical leadership positions at Takeda, Shire, Boston Scientific, Baxter, Novartis, and other leading healthcare organizations, guiding clinical development, global medical strategy, and life-cycle management across rare diseases, respiratory medicine, immunology, oncology, and transplantation. Today, he helps shape Takeda's global medical strategy for some of medicine's most challenging diseases, working closely with clinicians, researchers, and regulatory agencies around the world.Today we'll discuss why cytomegalovirus remains one of the greatest infectious threats facing organ transplant recipients, what we've learned from the latest research presented at the American Transplant Congress, how new antiviral therapies are changing the treatment landscape for patients with resistant or refractory CMV, and where the future of transplant medicine and infectious disease management is headed next.Important Episode Link -  LIVTENCITY® (maribavir) for Healthcare Professionalshttps://www.livtencity.com/#CMV #Cytomegalovirus #OrganTransplant #TransplantMedicine #Transplantation #Immunology #Virology #InfectiousDisease #Antiviral #DrugResistance #RareDisease #Biotechnology #Biotech #Pharmaceuticals #DrugDevelopment #PrecisionMedicine #MedicalInnovation #HealthcareInnovation #LifeSciences #MedicalResearch #AmericanTransplantCongress #ATC2026 #Maribavir #Takeda #ProgressPotentialAndPossibilitiesSupport the show

Send us Fan MailSpinal muscular atrophy (SMA) has undergone one of the most remarkable transformations in modern medicine. A disease that once carried devastating consequences, particularly in its most severe forms, can now be treated with therapies designed to dramatically alter its course - especially when treatment begins early.But medical progress creates a fascinating new question. What happens when you don't just change the disease - you change what's possible for the person living with it?Because today's SMA community includes children treated before symptoms emerge, young adults who have grown up in this new treatment era, and adults who have lived with SMA for decades and carry the consequences of disease that occurred before these therapies existed.And that's where our conversation today gets particularly interesting. Because the next challenge may not simply be developing better medicines. It may be helping people take full advantage of the lives those medicines make possible.My guest is Dr. Tracey Dawson, Ph.D., Senior Vice President and U.S. Therapeutic Area Head of Neuroscience at Novartis ( https://www.novartis.com/ ). Dr. Dawson brings more than 25 years of experience across neuroscience, rare diseases, biotechnology and pharmaceutical leadership - and today we're going to talk about the changing face of SMA, the evolution of the SMAshing My Limits initiative ( https://www.smashingmylimits.com/ ), and why Novartis is now turning its attention to something that might seem very different from drug development: helping people with SMA actually get out into the world.#SMA #SpinalMuscularAtrophy #SMAAwareness #SMAshingMyLimits #GeneTherapy #GeneTherapyRevolution #Neuroscience #RareDisease #RareDiseases #NeuromuscularDisease #Biotechnology #Biotech #Pharma #LifeSciences #PatientAdvocacy #AccessibleTravel #DisabilityInclusion #MedicalInnovation #HealthcareInnovation #Novartis #SMAResearch #FutureOfMedicine #ProgressPotentialAndPossibilitiesSupport the show

Send us Fan MailWhat if one of the biggest problems in cancer isn't that we don't have enough drugs to kill cancer cells - it's that the immune system sometimes can't see the cancer in the first place? There's a fascinating new strategy trying to change that: using a virus to make tumors more visible to the immune system.Today we're going to explore a fascinating and potentially transformative area of cancer medicine: oncolytic immunotherapy - using viruses or other immune-stimulating mechanisms to turn tumors from immunologically "cold" environments into tumors that the immune system can actually recognize and attack.Jared Kelly is the Chief Executive Officer and a Director of Oncolytics Biotech ( https://oncolyticsbiotech.com/ ), a company developing pelareorep, an investigational, intravenously delivered double-stranded RNA immunotherapy designed to activate the immune system and remodel the tumor microenvironment.Unlike many targeted cancer therapies that depend upon finding a particular mutation or surface antigen, pelareorep is designed to exploit a different vulnerability - using double-stranded RNA to trigger an inflammatory response, generate and activate tumor-reactive immune cells, and help those cells penetrate the tumor. The company's goal is ultimately to make the tumor more receptive to multiple other therapies.And Jared brings a rather unusual perspective to this story.  He's not a traditional biotech CEO who came up exclusively through drug discovery. He's an attorney and corporate strategist who spent years advising public companies and biotech companies on capital markets, M&A and corporate transactions before moving into biotech leadership.Previously at Ambrx, Jared served as Senior Vice President, General Counsel and Corporate Secretary and played a central role in the company's transformation, financing, licensing activities and eventual $2 billion acquisition by Johnson & Johnson. He subsequently became CEO of Oncolytics in June 2025.Today we're going to talk about the science of oncolytic immunotherapy, why the field may finally be reaching an inflection point, how pelareorep works, why the tumor microenvironment is so important, and perhaps most importantly - whether oncolytic immunotherapy could become the next major platform technology in oncology, in the same way that antibody-drug conjugates have rapidly moved from niche technology to mainstream cancer treatment.#Cancer #CancerResearch #CancerTreatment #CancerImmunotherapy #Immunotherapy #Oncology #OncolyticVirus #OncolyticViruses #Pelareorep #OncolyticsBiotech #Biotech #Biotechnology #DrugDevelopment #Pharma #PrecisionMedicine #TumorMicroenvironment #ImmunoOncology #KRAS #KRASCancer #ClinicalTrials #CancerScience #MedicalResearch #HealthcareInnovation #Science #Innovation #ProgressPotentialAndPossibilities #PPPSupport the show

Send us Fan MailIn biotech, discovering a drug is only half the battle. You have to understand the science, raise the capital, design the right clinical trials and convince the world that your hypothesis is worth pursuing.Today I'm joined by someone who has spent more than three decades at the intersection of science, medicine, business, and capital markets.Dr. David Crean, Ph.D. is the Chief Business Officer of MediciNova ( https://medicinova.com/ ), a clinical-stage biopharmaceutical company developing small-molecule therapies for neurodegenerative, inflammatory, fibrotic and other difficult-to-treat diseases. At MediciNova, Dr. Crean leads corporate development, partnering, investor relations and capital-markets strategy, and he has played a central role in communicating the company's scientific and strategic vision to investors and the broader life-sciences community.And Dr. Crean brings a pretty unusual perspective to that job.  He's not simply a business executive who entered biotech from the financial world. He holds a Ph.D. in Biophysics, began his career doing biomedical research, spent years involved in drug development and portfolio management, and then moved into corporate development and strategic transactions.At Allergan, Dr. Crean spent more than a decade working across neurology, medical aesthetics, dermatology, ophthalmology and other therapeutic areas, ultimately negotiating and closing more than 30 strategic transactions involving acquisitions, licensing, partnerships and equity investments.Since then, Dr. Crean has advised more than 250 life-science and healthcare companies and been involved in more than 50 transactions representing more than a billion dollars in aggregate value.But what is particularly fascinating about Dr. Crean's career is that he's repeatedly occupied the space between science and capital - helping scientists and entrepreneurs translate great science into something that can actually be financed, developed, partnered, commercialized and delivered to patients.And that brings us to MediciNova.The company's lead program is MN-166, or ibudilast, an orally available small molecule with anti-inflammatory and neuroprotective properties that is being developed across several neurological diseases, including ALS, progressive multiple sclerosis and degenerative cervical myelopathy, with additional investigations in areas including glioblastoma, Long COVID and chemotherapy-induced peripheral neuropathy.The ALS program is especially interesting because MediciNova has now completed enrollment in its Phase 2b/3 COMBAT-ALS study, while a separate NIH-supported expanded-access study, SEANOBI-ALS, reached its target enrollment of 200 patients this summer.And Dr. Crean has another fascinating project underway: his forthcoming book, Dual Fluency: How Life Sciences Leaders Master the Language of Science and Capital ( https://dual-fluency.com/ ), which explores the idea that leaders in biotech need to be fluent in both the language of scientific discovery and the language of investors, partners and business.So today we're going to talk about ALS and the science behind MediciNova - but also about something much bigger: What does it actually take to turn scientific potential into a successful medicine and a successful company?#ALS #AmyotrophicLateralSclerosis #Ibudilast #MediciNova #NeurodegenerativeDisease #Neuroscience #Neuroinflammation #Microglia #DrugRepurposing #Biotechnology #Biotech #Pharmaceuticals #DrugDevelopment #ClinicalTrials #Neurology #MotorNeurons #BrainHealth #MedicalResearch #Science #Innovation #LifeSciences #Healthcare #Pharma #ProgressPotentialAndPossibilitiesSupport the show

Send us Fan MailCancer doesn't just sit there while we attack it. It evolves.We give a patient a powerful drug. The tumor shrinks. It looks like we've won.But somewhere inside that tumor may be a small population of cells that figured out how to survive. Those cells can eventually multiply, the cancer returns, and the drug that once worked no longer works.So what if, instead of continually chasing cancer with newer and newer drugs, we could turn off the biological escape routes that allow cancer to become resistant in the first place?Dr. John Yu, MD is the Founder and CEO of Kairos Pharma ( https://kairospharma.com/ ), a clinical-stage oncology company spun out of Cedars-Sinai Medical Center that is developing therapies designed to overcome cancer drug resistance and immune suppression.Dr. Yu is also Professor and Clinical Chief of Neurosurgery at Cedars-Sinai and Director of Surgical Neuro-Oncology ( https://www.cedars-sinai.org/provider/john-yu-2181236.html ). His career sits at a fascinating intersection of neurosurgery, immunology and cancer biology.Dr. Yu earned undergraduate degrees in biology and French from Stanford University, his MD from Harvard Medical School through the Harvard-MIT program, completed his neurosurgery residency at Massachusetts General Hospital, and pursued immunology research at the Institut Pasteur in Paris.Over the course of his career, Dr. Yu has developed eight FDA investigational drugs and holds multiple patents spanning immunotherapy and nanotechnology.At Kairos, that scientific journey has led to a particularly interesting strategy: targeting CD105, also known as endoglin, a protein that appears to become elevated as tumors develop resistance to certain cancer therapies.The company's lead candidate, ENV105, is an antibody designed to inhibit CD105 and potentially re-sensitize resistant tumors to therapies that had stopped working. Kairos is currently evaluating ENV105 in Phase 2 prostate cancer and Phase 1 lung cancer studies.On this episode we talk about one of the great challenges in modern oncology - why cancer becomes resistant, whether that resistance can actually be reversed, and whether we can turn some of our existing cancer drugs back into powerful weapons against the disease.#Cancer #CancerResearch #CancerTreatment #CancerDrugResistance #Oncology #Immunotherapy #PrecisionMedicine #Biotechnology #Biotech #DrugDevelopment #CancerTherapy #ProstateCancer #LungCancer #LungCancerResearch #ProstateCancerResearch #ImmunoOncology #TargetedTherapy #DrugResistance #CancerBiology #CD105 #Endoglin #ENV105 #KairosPharma #JohnYu #MedicalResearch #Pharma #HealthcareInnovation #CancerScience #ClinicalTrials #ProgressPotentialAndPossibilitiesSupport the show